trending Market Intelligence /marketintelligence/en/news-insights/trending/2zw65d-bka121ooxvlyudw2 content esgSubNav
In This List

Midatech liver cancer medicine receives EMA's orphan drug tag

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Midatech liver cancer medicine receives EMA's orphan drug tag

U.K.-based biotech company Midatech Pharma PLC said its liver cancer medicine MTD119 received the European Medicines Agency's orphan drug designation.

The drug is being developed as a potential treatment for hepatocellular carcinoma, a rare cancer that develops in people with chronic liver diseases.

A recent pre-clinical study comparing the efficacy of MTD119 with the current standard of care — Bayer AG's Nexavar or sorafenib demonstrated Midatech's drug could work better in the affected patient population.

The EMA's orphan drug designation is meant for medicines that target a rare condition which impacts no more than 5 in 10,000 people in the EU. It is meant to expedite development of a drug by offering incentives and protection from competition once the medicine is commercialized.